Biomx Inc (NYSE MKT:PHGE) — Market Cap & Net Worth
Market Cap & Net Worth: Biomx Inc (PHGE)
Biomx Inc (NYSE MKT:PHGE) has a market capitalization of $1.25 Million ($1.25 Million) as of September 16, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #30564 globally and #6218 in its home market, demonstrating a 39.85% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biomx Inc's stock price $0.82 by its total outstanding shares 1526640 (1.53 Million). Also see Biomx Inc total assets for a full breakdown of the balance sheet.
Biomx Inc Market Cap History: 2019 to 2026
Biomx Inc's market capitalization history from 2019 to 2026. Data shows change from $147.86 Million to $1.25 Million (-48.47% CAGR). Also see Biomx Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Biomx Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biomx Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Biomx Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
-11.97x
Biomx Inc's market cap is -11.97 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $2.85 Million | $-134.00K | -$28.32 Million | -21.30x | N/A |
| 2023 | $4.27 Million | $-357.00K | -$26.17 Million | -11.97x | N/A |
Competitor Companies of PHGE by Market Capitalization
Companies near Biomx Inc in the global market cap rankings as of September 16, 2026. Review PHGE intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Biomx Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #338 globally with a market cap of $80.28 Billion USD.
- CSL Ltd (AU:CSL): Ranked #463 globally with a market cap of $58.90 Billion USD ( AU$83.24 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $519.51 |
| #338 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.28 Billion | $793.74 |
| #463 | CSL Ltd | AU:CSL | $58.90 Billion | AU$171.57 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $146.69 |
Biomx Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Biomx Inc's market cap moved from $147.86 Million to $ 1.25 Million, with a yearly change of -48.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.25 Million | -56.31% |
| 2025 | $2.85 Million | +156.13% |
| 2024 | $1.11 Million | -73.92% |
| 2023 | $4.27 Million | +49.73% |
| 2022 | $2.85 Million | -88.31% |
| 2021 | $24.43 Million | -74.92% |
| 2020 | $97.40 Million | -34.12% |
| 2019 | $147.86 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of Biomx Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.25 Million USD |
| MoneyControl | $1.25 Million USD |
| MarketWatch | $1.25 Million USD |
| marketcap.company | $1.25 Million USD |
| Reuters | $1.25 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biomx Inc
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic f… Read more